Compare AbbVie Inc (ABBV) vs Toyota Motor Corp (TM) Price & Performance

AbbVie (ABBV) trades at $252.63, down 0.84% on the day, with a bullish technical signal and strong support at $248. The stock shows robust fundamentals with revenue growth to $61.16B in 2025 and consistent earnings beats, though net margins have compressed to 5.79%. Recent news highlights positive Phase 2 trial data for ELAHERE in ovarian cancer and institutional accumulation, reinforcing growth prospects beyond Humira's patent expiry.

Outlook remains positive with a consensus price target of $266.33 (5.4% upside), supported by 68% analyst buy ratings. Key opportunities include immunology drugs Skyrizi and Rinvoq driving growth, but risks involve patent cliffs in the 2030s, high debt levels, and regulatory pressures on drug pricing. The stock offers a resilient dividend with recent increases, appealing for income-focused investors amid sector volatility.

Toyota Motor (TM) trades at $179.43, up 2.77% today, with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with a P/E of 9.85 and consistent earnings beats, including Q1 2026 EPS of $4.00 versus $3.11 expected. Recent news highlights a $3.6 billion Texas plant expansion to shift Tacoma production from Mexico, signaling strategic US investment. Operating cash flow remains robust at $3.70 trillion for 2025, though net cash flow turned negative due to significant capital expenditures.

Toyota presents a compelling value opportunity with attractive valuation multiples and hybrid vehicle leadership, but faces risks from declining global sales and rising debt levels. Analyst sentiment is mixed with 37.5% buy ratings versus 62.5% hold, reflecting cautious optimism amid competitive pressures. The stock's current technical strength near resistance at $180-183 suggests potential for near-term consolidation before further upside.